J&J Agrees to $5.5B Talcum Powder Settlement Payout to Resolve Ovarian Cancer Lawsuits

Agreement provides at least $5.5 billion in settlement benefits for women who have filed ovarian cancer lawsuits, with individual payouts based on qualifying criteria and the severity of claimant injuries.

A settlement announced this week could resolve nearly 80,000 talcum powder lawsuits, bringing an end to more than a decade of litigation involving allegations that asbestos-contaminated talc products caused ovarian cancer among women who used the products around their genital areas.

In a press release issued on July 27, Johnson & Johnson said it reached a proposed $5.5 billion agreement with leading plaintiff law firms involved in the federal multidistrict litigation and related state court proceedings. The deal remains contingent on several conditions, including participation by at least 95% of the remaining claimants.

The company currently faces approximately 76,000 Johnson’s Baby Powder lawsuits and Shower-to-Shower lawsuits pending in courts nationwide. The claims generally allege that long-term use of talc-based products contributed to the development of ovarian cancer and other reproductive cancers, and that Johnson & Johnson knew about the potential health risks for decades while continuing to market the products for feminine hygiene use.

Due to the mounting number of claims filed, consolidated federal litigation was established more than 10 years ago, when the U.S. Judicial Panel on Multidistrict Litigation centralized the claims in the District of New Jersey as part of a talcum powder lawsuit MDL, which is being overseen by U.S. District Judge Michael A. Shipp.

As the litigation faced repeated hurdles, including Johnson & Johnson’s unsuccessful efforts to resolve the claims through bankruptcy proceedings, Judge Shipp appointed a special mediator in 2025 and directed the parties to participate in settlement negotiations, including a mediation session scheduled for April 2026.

Talcum Powder Lawsuit Settlement Offer

Those negotiations have now resulted in a proposed resolution. According to Johnson & Johnson’s July 27 press release, the company has committed at least $5.5 billion to resolve the ovarian cancer claims currently pending in federal and state courts, with an initial payment of up to $3 billion scheduled for 2027. No additional payments would be due before 2028.

The agreement is not structured as a typical settlement that caps Johnson & Johnson’s total liability at $5.5 billion. Instead, that amount represents the minimum commitment for existing claims, with individual payments expected to be determined by qualifying criteria and the severity of each claimant’s diagnosis and injuries.

The total cost could exceed $5.5 billion if additional qualifying cases are included. The agreement also would not prevent women from filing future talcum powder lawsuits or potentially receiving compensation if they are later diagnosed with ovarian cancer after using Johnson’s Baby Powder, Shower-to-Shower or other talc-based products.

The proposed agreement comes after prior attempts were made to settle talcum powder lawsuits through bankruptcy proceedings, including a prior $9 billion offer that would have not only resolved current lawsuits but also provided a fund for women diagnosed in the future. That effort was rejected after the court found the bankruptcy strategy was an improper attempt to resolve the company’s talc liabilities.

Johnson & Johnson attributes the reduced amount to recent developments in the federal litigation, including the withdrawal of plaintiffs’ specific-causation experts in two planned bellwether cases. The company argues those experts were necessary to establish that talcum powder use caused each individual claimant’s ovarian cancer.

Before the settlement can move forward, participating law firms must represent at least 95% of the remaining ovarian cancer claims. Johnson & Johnson continues to maintain that its talc products are safe and do not cause cancer, despite discontinuing talc-based Baby Powder worldwide in 2023 and separating its consumer products business into Kenvue that same year.

Sign up for more legal news that could affect you or your family.